Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

9. november 2026 oppdatert av: GlaxoSmithKline

Fase 3, multisenter, randomisert, åpen etikett klinisk studie av GSK5764227, et B7-H3-antistoffmedisinsk konjugat (ADC), sammenlignet med topotekan hos deltakere med tilbakefallte småcellet lungekreft (SCLC)

In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancer's ability to grow and spread. This study specifically aims to evaluate how well Ris-Rez works in treating relapsed SCLC compared to standard treatment topotecan, by checking whether Ris-Rez makes cancers smaller or disappear completely and if it helps participants live longer. The study is also assessing whether Ris-Rez is safe and tolerated well by participants compared to topotecan and provide a better understanding of the main side effects of both drugs. Participants with relapsed SCLC will be randomly divided into two groups: one group receiving Ris-Rez and the other receiving topotecan.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

420

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

      • Buenos Aires, Argentina, C1426ABP
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Christian Fuentes
      • Ciudad Autonoma de Buenos Aire, Argentina, C1012AAR
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Pedro Martin Paskevicius
      • Ciudad Autonoma de Buenos Aire, Argentina, C1426AGE
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Nicolas Minatta
      • Rosario, Argentina, S2000 DEJ
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Gabriel Garbaos
      • Vicente López, Argentina, 1602
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Gustavo Lopez
    • Buenos Aires
      • Mar del Plata, Buenos Aires, Argentina, 7600
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ignacio Casarini
    • New South Wales
      • Blacktown, New South Wales, Australia, 2148
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Emma Boys
      • St Leonards, New South Wales, Australia, 2065
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Malinda Itchins
    • Victoria
      • Melbourne, Victoria, Australia, 3000
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Benjamin Solomon
    • Western Australia
      • Nedlands, Western Australia, Australia, 6009
        • Tilbaketrukket
        • GSK Investigational Site
      • Barretos, Brasil, 14784-400
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Flavio Augusto Ferreira da Silva
      • CuritibaPR, Brasil, 80810-050
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Karina Costa Maia Vianna
      • Porto Alegre, Brasil, 90610-000
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ana Gelatti
      • Porto Alegre, Brasil, 90020-090
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Katsuki Tiscoski
        • Ta kontakt med:
        • Ta kontakt med:
      • Rio de Janeiro, Brasil, 22250-905
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tatiane Montella
      • São Paulo, Brasil, 04312903
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Gilberto De Castro Junior
        • Ta kontakt med:
        • Ta kontakt med:
    • Santa Catarina
      • Florianópolis, Santa Catarina, Brasil, 88020-210
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • fabricio grando
      • Pleven, Bulgaria, 5800
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Yordan Ignatov
      • Plovdiv, Bulgaria
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Vladimir Kanarev
        • Ta kontakt med:
        • Ta kontakt med:
      • Rousse, Bulgaria, 7002
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Nikolay Nikolaev
      • Sofia, Bulgaria, 1606
        • Tilbaketrukket
        • GSK Investigational Site
      • Sofia, Bulgaria, 1303
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Krasimir Koynov
    • Ontario
      • Ottawa, Ontario, Canada, K1H 8L6
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Paul Wheatley-Price
      • Toronto, Ontario, Canada, M5G 1Z5
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Natasha Leighl
    • Quebec
      • Montreal, Quebec, Canada, H3T 1E2
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jennifer Friedmann
      • Montreal, Quebec, Canada, H4J 1C5
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kevin Jao
      • Vaasa, Finland, 65130
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ravichandra Ravi
    • California
      • Los Angeles, California, Forente stater, 90027
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Ghassan Al-Jazayrly
        • Ta kontakt med:
        • Ta kontakt med:
    • Florida
      • Hialeah, Florida, Forente stater, 33013
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Luis Rangel
      • Miami, Florida, Forente stater, 33176
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Francisco Belette
      • Plantation, Florida, Forente stater, 33322-5426
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Jason Tache
        • Ta kontakt med:
        • Ta kontakt med:
      • Tamarac, Florida, Forente stater, 33321
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Andrew Schneider
    • Illinois
      • Hinsdale, Illinois, Forente stater, 60521
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Srilata Gundala
    • New York
      • East Syracuse, New York, Forente stater, 13057
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ajeet Gajra
    • North Carolina
      • Wilson, North Carolina, Forente stater, 27893-3484
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Keith Lerro
    • Ohio
      • Canton, Ohio, Forente stater, 44718
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Nashat Gabrail
    • Texas
      • Fort Worth, Texas, Forente stater, 76104
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Latha Neerukonda
      • Boulogne-Billancourt, Frankrike, 92100
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Etienne Giroux Leprieur
      • Grenoble, Frankrike, 38043
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Denis Moro-Sibilot
        • Ta kontakt med:
        • Ta kontakt med:
      • Saint-Herblain, Frankrike, 44805
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Sandrine Hiret
        • Ta kontakt med:
        • Ta kontakt med:
      • Villejuif, Frankrike, 94805
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Pernelle Lavaud
      • Athens, Hellas, 12462
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Amanda Psyrri
      • Athens, Hellas, 115 22
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • ANASTASIOS GRIVAS
      • Pylaia Thessaloniki, Hellas, 57001
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Ippokratis Korantzis
        • Ta kontakt med:
        • Ta kontakt med:
      • Pylaia Thessaloniki, Hellas, 570 01
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Sofia Baka
    • Attica
      • Athens, Attica, Hellas, 115 26
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ioannis Mountzios
    • Crete
      • Heraklion, Crete, Hellas, 700 13
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Sofia Agelaki
      • Dublin, Irland, D09 V2N0
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jarushka Naidoo
      • Jerusalem, Israel, 9112001
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Yakir Rottenberg
      • Tel Aviv, Israel, 6423906
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • ido wolf
      • Bergamo, Italia
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Chiara Catania
      • Genova, Italia, 16132
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Francesco Grossi
        • Ta kontakt med:
        • Ta kontakt med:
      • Orbassano, Italia, 10043
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Francesco Passiglia
      • Pisa, Italia, 57124
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Giacomo Allegrini
      • Siena, Italia, 53100
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Michele Maio
      • Verona, Italia, 37134
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jessica Menis
    • MI
      • Milan, MI, Italia, 20141
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Antonio Passaro
    • RM
      • Roma, RM, Italia, 00168
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Emilio Bria
        • Ta kontakt med:
        • Ta kontakt med:
      • Fukuoka, Japan, 812-8582
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Isamu Okamoto
        • Ta kontakt med:
        • Ta kontakt med:
      • Hokkaido, Japan, 060-8648
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Yasuyuki Ikezawa
      • Ishikawa, Japan, 920-8530
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Takashi Sone
      • Kagoshima, Japan, 890-8520
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Shunsuke Misono
      • Kanagawa, Japan, 241-8515
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Shuji Murakami
      • Kanagawa, Japan, 252-0375
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Katsuhiko Naoki
      • Kochi, Japan, 783-8505
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Hovedetterforsker:
          • Toshiyuki Kozuki
        • Ta kontakt med:
      • Kyoto, Japan, 612-8555
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kohei Fujita
      • Mie, Japan, 515-8544
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Osamu Hataji
      • Miyagi, Japan, 980-8574
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Hovedetterforsker:
          • Eisaku Miyauchi
        • Ta kontakt med:
      • Osaka, Japan, 541-8567
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • takako inoue
      • Osaka, Japan, 573-1191
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Takayasu Kurata
      • Osaka, Japan, 594-0073
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Takafumi Okabe
      • Tokyo, Japan, 113-8603
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kazuo Kasahara
      • Tokyo, Japan, 104-0045
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Yasushi Goto
      • Tokyo, Japan, 113-8677
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Yukio Hosomi
      • Toyama, Japan, 930-8550
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Hirokazu Taniguchi
        • Ta kontakt med:
        • Ta kontakt med:
      • Guadajalara, Mexico, 44280
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Juan Carlos Vazquez Limon
      • Mexico City, Mexico, 06760
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Raul Rogelio Trejo-Rosales
      • Mexico City, Mexico, 06700
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Eleazar Omar Macedo-Perez
        • Ta kontakt med:
        • Ta kontakt med:
    • Nuevo León
      • San Pedro Garza García, Nuevo León, Mexico, 66260
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Hector Marcelino Diaz-Perez
      • Gliwice, Polen, 44-102
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Grzegorz Slomian
      • Kielce, Polen, 25-640
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tomasz Kucharczyk
      • Lodz, Polen, 93-338
        • Tilbaketrukket
        • GSK Investigational Site
      • Olsztyn, Polen, 10-357
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jarosław Kołb-Sielecki
      • Otwock, Polen, 05-400
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Aleksandra Szczesna
      • Poznan, Polen, 60-569
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Katarzyna Stencel
      • Przemyśl, Polen, 37-700
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kamil Kuc
      • Siedlce, Polen, 08-110
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Lubomir Bodnar
      • Coimbra, Portugal, 3000-075
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Sara Póvoa
      • Guimarães, Portugal, 4835-044
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Pedro Brito
      • Lisbon, Portugal, 1400-038
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Patrícia Garrido
    • Setúbal District
      • Almada, Setúbal District, Portugal, 2805-267
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Miguel Lopes
      • Cluj-Napoca, Romania, 400015
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Cristina Ligia Cebotaru
        • Ta kontakt med:
        • Ta kontakt med:
      • Craiova, Romania, 200542
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Michael Schenker
      • Floreşti, Romania, 407280
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Andrei Ungureanu
      • Iași, Romania, 700451
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Teodora Alexa Stratulat
      • Timișoara, Romania, 300329
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • DANIELA SIRBU
    • Dolj
      • Craiova Dolj, Dolj, Romania, 200535
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Cristian Lungulescu
      • Barcelona, Spania, 08003
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Edurne Arriola Aperribay
        • Ta kontakt med:
        • Ta kontakt med:
      • Barcelona, Spania, 08035
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Pedro Rocha
      • Barcelona, Spania, 8036
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Noemi Reguart Aransay
        • Ta kontakt med:
        • Ta kontakt med:
      • L'Hospitalet de Llobrega, Spania, 08908
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Miguel Ángel Mosteiro Lamas
      • Las Palmas de Gran Canar, Spania, 35016
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Delvys Rodriguez-Abreu
      • Madrid, Spania, 28046
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Javier Francisco De Castro Carpeño
      • Madrid, Spania, 28034
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • María Eugenia Olmedo García
      • Madrid, Spania, 28041
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Luis Paz-Ares
        • Ta kontakt med:
        • Ta kontakt med:
      • Madrid, Spania, 28007
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Rosa Alvarez Alvarez
        • Ta kontakt med:
        • Ta kontakt med:
      • Santander, Spania, 39011
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Marta Lopez-Brea Piqueras
        • Ta kontakt med:
        • Ta kontakt med:
      • London, Storbritannia, W1G 6AD
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Anja Williams
        • Ta kontakt med:
        • Ta kontakt med:
      • Portsmouth, Storbritannia, PO6 3LY
        • Tilbaketrukket
        • GSK Investigational Site
      • Truro, Storbritannia, TR1 3LJ
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Grant Stewart
      • Basel, Sveits, 4031
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Andreas Schmitt
      • Lausanne, Sveits, 1011
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Nuria Neisy Mederos Alfonso
      • Stockholm, Sverige, 171 64
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Hannah Björn Andtback
      • Changwon, Sør -Korea, 51472
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Junho Ji
      • Cheongju Chungcheongbuk-do, Sør -Korea, 28644
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Ki Hyeong Lee
        • Ta kontakt med:
        • Ta kontakt med:
      • Daegu, Sør -Korea, 41404
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Seung Soo Yoo
      • Gyeonggi-do, Sør -Korea, 10408
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Beung Chul Ahn
      • Seongnam-si Gyeonggi-do, Sør -Korea, 13620
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Yu Jung Kim
      • Seoul, Sør -Korea, 03722
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Hye Ryun Kim
      • Suwon Gyeonggi-do, Sør -Korea, 442723
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Byoung Yong Shim
      • Ulsan, Sør -Korea, 44033
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Cheol Kyung Sin
      • Ankara, Tyrkia (Türkiye), 06010
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ismail Erturk
      • Ankara, Tyrkia (Türkiye), 06520
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Umut Demirci
      • Ankara, Tyrkia (Türkiye), 6230
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Mustafa Erman
        • Ta kontakt med:
        • Ta kontakt med:
      • Diyarbakır, Tyrkia (Türkiye), 21280
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Muhammet Kaplan
      • Istanbul, Tyrkia (Türkiye), 34010
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Seyda Gunduz
        • Ta kontakt med:
        • Ta kontakt med:
      • Izmir, Tyrkia (Türkiye), 35110
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Sema Erturk
      • Izmir, Tyrkia (Türkiye), 35340
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Elif Atag
    • Adana
      • Adana, Adana, Tyrkia (Türkiye), 01140
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ahmet Sumbul
    • Atakum
      • Samsun, Atakum, Tyrkia (Türkiye), 55200
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Dilek Erdem
      • Augsburg, Tyskland, 86156
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bjoern Hackanson
      • Chemnitz, Tyskland, 09113
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Stefan Hammerschmidt
      • Esslingen am Neckar, Tyskland, 73730
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Martin Faehling
      • Heidelberg, Tyskland, 69126
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Johannes Schnorbach
      • Immenhausen, Tyskland, 34376
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Achim Rittmeyer
        • Ta kontakt med:
        • Ta kontakt med:
      • Lübeck, Tyskland, 23562
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Jens Kisro
        • Ta kontakt med:
        • Ta kontakt med:
      • München, Tyskland, 81377
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Diego Kauffmann-Guerrero
      • Nuremberg, Tyskland, 90340
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Markus Horneber
      • Regensburg, Tyskland, 93053
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Christian Schulz
    • Baden-Wurttemberg
      • Karlsruhe, Baden-Wurttemberg, Tyskland, 76137
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Christian Meyer zum Bueschenfelde
        • Ta kontakt med:
        • Ta kontakt med:
      • Löwenstein, Baden-Wurttemberg, Tyskland, 74245
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Jonas Kuon
        • Ta kontakt med:
        • Ta kontakt med:
      • Stuttgart, Baden-Wurttemberg, Tyskland, 70376
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Perihan Canoglu
      • Budapest, Ungarn, H-1121
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Gabriella Temesi
      • Farkasgyepű, Ungarn, 8552
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Zsolt Király
      • Gyöngyös, Ungarn, 3200
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • István Albert
      • Kecskemét, Ungarn, 6000
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Zsuzsanna Kelemen
      • Székesfehérvár, Ungarn, 8000
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Zsolt Pápai Székely
      • Törökbálint, Ungarn, 2045
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Gabriella Gálffy

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

Participants are eligible to be included in the study only if all of the following criteria apply:

  • Adults >18 or the minimum legal adult age at the time the informed consent form is signed
  • Has histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).
  • Has received 1 prior platinum-based systemic therapy with a PD- (L)1 inhibitor for at least 2 cycles of therapy and a chemotherapy free-interval of >30 days, with documented progression. Participants with prior tarlatamab treatment in either the first- or second-line ES-SCLC setting are eligible.
  • Has at least 1 target lesion per RECIST 1.1, as determined by the investigator.
  • Is capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the ICF and in the protocol.
  • Has adequate organ function and an ECOG performance status of 0 or 1

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Pathological diagnosis of complex SCLC or transformed SCLC.
  • Limited stage small cell lung cancer at diagnosis
  • Has received any prior therapy with an Antibody-drug conjugate (ADC) with a Topoisomerase-1 (TOPO1)-inhibitor payload or treatments targeting B7-H3.
  • Has known sensitivity to study intervention components or excipients or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.
  • Has severe, uncontrolled or active cardiovascular disorders.
  • Has clinically significant bleeding symptoms or significant bleeding tendency within 1 month prior to the first dose.
  • Known active infectious diseases requiring systemic treatment or known Human immunodeficiency virus (HIV).
  • Has symptomatic brain metastases or untreated progression exclusively due to brain metastasis during or after the last treatment prior to screening, evidence of leptomeningeal/meningeal/brainstem metastasis or evidence of spinal cord metastases.
  • Has any evidence of current interstitial lung disease or pneumonitis or a prior history of ILD or non-infectious pneumonitis requiring high dose steroids.
  • Has significant pulmonary disease or respiratory impairment (e.g., uncontrolled asthma/COPD, restrictive lung disease),
  • Has active Hepatitis B or Hepatitis C

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Topotekan

Topotecan will be administered

Eksperimentell: Risvutatug rezetecan (Ris-Rez)

Ris-Rez will be administered

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Overall Survival (OS)
Tidsramme: Up to approximately 113 weeks

OS is defined as the time from the date of randomization to the date of death by any cause

Up to approximately 113 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Antall deltakere med bivirkninger (AE), alvorlige bivirkninger (SAE) og bivirkninger av spesiell interesse (AESI) etter alvorlighetsgrad
Tidsramme: Opptil ca. 139 uker
Opptil ca. 139 uker
Antall deltakere med uønskede hendelser som fører til dosejusteringer eller avslutning av studieintervensjon
Tidsramme: Opp til omtrent 139 uker
Opp til omtrent 139 uker
Observerte PK-konsentrasjoner av Ris-Rez (konjugert antistoff og lite molekyllast)
Tidsramme: Opptil cirka 139 uker
Opptil cirka 139 uker
Antall deltakere med antimedikament-antistoff (ADA) eller nøytraliserende antistoff (NAb)
Tidsramme: Opptil omtrent 139 uker
Opptil omtrent 139 uker
Titere av ADA mot Ris-Rez
Tidsramme: Opptil ca. 139 uker
Opptil ca. 139 uker
Brain PFS
Tidsramme: Up to approximately 139 weeks

Brain PFS is defined as the time from the date of randomization to the date of first documented PD per modified Response assessment in neuro-oncology (RANO-BM) by BICR assessment or death from any cause, whichever occurs first in participants with history of brain metastasis or presence of brain metastasis at baseline

Up to approximately 139 weeks
Change from baseline in cough
Tidsramme: Up to approximately 18 weeks

Validated questionnaires will be used for the assessment

Up to approximately 18 weeks
Change from baseline in dyspnea
Tidsramme: Up to approximately 18 weeks

Validated questionnaires will be used for the assessment

Up to approximately 18 weeks
Change from baseline in chest pain
Tidsramme: Up to approximately 18 weeks

Validated questionnaires will be used for the assessment

Up to approximately 18 weeks
Time to clinical deterioration in physical functioning
Tidsramme: Up to approximately 139 weeks

Time to clinical deterioration in physical functioning will be measured using validated questionnaires

Up to approximately 139 weeks
Objective Response Rate (ORR)
Tidsramme: Up to approximately 139 weeks

ORR is defined as the percentage of participants with a confirmed complete (CR) or confirmed partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by investigator/Blinded Independent Central Review (BICR) assessment

Up to approximately 139 weeks
Duration of Response (DoR)
Tidsramme: Up to approximately 139 weeks

DoR is defined as the time from the date of first documented objective response (CR or PR) per RECIST 1.1 by investigator/BICR assessment to the date of first documented PD per RECIST 1.1 by investigator/BICR assessment or death due to any cause, whichever comes first

Up to approximately 139 weeks
Progression-free survival (PFS)
Tidsramme: Up to approximately 139 weeks

PFS is defined as the time from the date of randomization to the date of first documented Progressive disease (PD) per RECIST 1.1 by investigator/BICR assessment or death from any cause, whichever occurs first

Up to approximately 139 weeks
Disease control rate (DCR) 12
Tidsramme: Up to approximately 11 weeks

DCR12 is defined as the percentage of participants who have a Best objective response (BOR) of confirmed CR, confirmed PR, or Stable Disease (SD) for a duration of at least 11 weeks, per RECIST 1.1 by investigator/BICR assessment

Up to approximately 11 weeks
Brain DoR
Tidsramme: Up to approximately 139 weeks

Brain DoR is defined as the time from the first documented objective response (CR/PR according to modified RANO-BM BICR assessment) until the time of first documentation of disease progression or death, whichever occurs first, in participants with a history of brain metastasis or presence of brain metastasis at baseline

Up to approximately 139 weeks
Brain ORR
Tidsramme: Up to approximately 139 weeks

Brain ORR is defined as the percentage of participants with confirmed brain CR or confirmed brain PR per modified RANO-BM BICR assessment in participants with a history of brain metastasis or presence of brain metastasis at baseline

Up to approximately 139 weeks
Brain DCR12
Tidsramme: Up to approximately 11 weeks

Brain DCR12 is defined as the percentage of participants with an intracranial BOR of confirmed CR, confirmed PR or SD after the date of randomization, per modified RANO-BM BICR assessment in participants with a history of brain metastasis or presence of brain metastasis at baseline

Up to approximately 11 weeks
Time to brain progression
Tidsramme: Up to approximately 139 weeks

Time to brain progression is defined as the time from the date of randomization to the date of first documented brain PD per modified RANO-BM BICR assessment in participants with a history of brain metastasis or presence of brain metastasis at baseline.

Up to approximately 139 weeks
Number of participants with a change from baseline in vital signs
Tidsramme: Baseline (Day -1) and up to approximately 139 weeks

Number of participants will be assessed.

Baseline (Day -1) and up to approximately 139 weeks
Number of participants with a change from baseline in laboratory parameters (hematology and clinical chemistry)
Tidsramme: Baseline (Day -1) and up to approximately 139 weeks

Number of participants will be assessed.

Baseline (Day -1) and up to approximately 139 weeks
Number of participants with a change from baseline in cardiac function [Electrocardiogram (ECG)
Tidsramme: Baseline (Day -1) and up to approximately 139 weeks

Number of participants will be assessed.

Baseline (Day -1) and up to approximately 139 weeks
Number of participants with a change from baseline in Eastern Cooperative Oncology Group (ECOG) performance status
Tidsramme: Baseline (Day -1) and up to approximately 139 weeks

Number of participants will be assessed.

Baseline (Day -1) and up to approximately 139 weeks
Participant reported experience with study treatment
Tidsramme: Up to approximately 139 weeks

Participant reported outcomes assessing symptoms, daily functioning, and overall health status during study treatment will be measured using validated questionnaires

Up to approximately 139 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

11. august 2025

Primær fullføring (Antatt)

5. november 2027

Studiet fullført (Antatt)

28. september 2029

Datoer for studieregistrering

Først innsendt

30. juli 2025

Først innsendt som oppfylte QC-kriteriene

30. juli 2025

Først lagt ut (Faktiske)

1. august 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

IPD-delingstidsramme

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Tilgangskriterier for IPD-deling

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • ICF
  • CSR

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere